Blood test mismatch reveals hidden kidney trouble doctors often miss

Two common kidney tests should tell the same story. When they don't, something serious might be quietly unfolding.

Researchers at NYU Langone Health analyzed nearly 900,000 patient records across six countries and found that when creatinine and cystatin C—the two main markers doctors use to assess kidney function—give conflicting results, the risk of kidney failure, heart disease, and death rises sharply. More than one third of hospitalized patients in the study showed cystatin C results suggesting their kidneys were working at least 30% worse than creatinine levels indicated. That gap matters. A lot.

"Our findings highlight the importance of measuring both creatinine and cystatin C to gain a true understanding of how well the kidneys are working, particularly among older and sicker adults," said Morgan Grams, MD, PhD, one of the study's lead researchers. "Evaluating both biomarkers may identify far more people with poor kidney function, and earlier in the disease process, by covering the blind spots that go with either test."

Why This Gap Matters

The mismatch isn't just a statistical curiosity. Kidney function determines how your body processes and eliminates medications. Oncologists use it to calculate safe doses of cancer treatments. Doctors rely on it when prescribing antibiotics, heart medications, and dozens of other common drugs. Get the kidney assessment wrong, and you risk either underdosing (leaving disease untreated) or overdosing (causing harm).

The international team found that patients whose cystatin C results showed significantly worse kidney function than their creatinine suggested faced substantially higher risks across the board: more likely to develop severe chronic kidney disease, more likely to experience heart failure, more likely to die during the study period. These weren't marginal increases. The signal was clear.

What makes this finding particularly important is that cystatin C testing is becoming more available. Many hospitals and clinics now offer it alongside the standard creatinine test. But knowing you can measure both doesn't mean doctors are actually doing it—or interpreting what happens when the results disagree.

"Physicians might otherwise miss out on valuable information about their patients' well-being and future medical concerns," said Josef Coresh, MD, PhD, the study's other lead researcher. The blind spot is real, and it's hiding in plain sight: two test results that don't match, sitting in a patient's file, waiting to be noticed.

The research, funded by the National Institutes of Health and the National Kidney Foundation, suggests a straightforward next step. When these two markers diverge, it's not a lab error to overlook. It's a signal worth taking seriously.